Quantum Private Wealth LLC Has $229,000 Stock Holdings in Solid Biosciences Inc. (NASDAQ:SLDB)

Quantum Private Wealth LLC raised its position in shares of Solid Biosciences Inc. (NASDAQ:SLDB) by 81.8% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 57,333 shares of the company’s stock after purchasing an additional 25,800 shares during the period. Quantum Private Wealth LLC owned approximately 0.14% of Solid Biosciences worth $229,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in the company. China Universal Asset Management Co. Ltd. bought a new position in shares of Solid Biosciences in the 4th quarter valued at $34,000. The Manufacturers Life Insurance Company bought a new position in Solid Biosciences in the third quarter valued at about $71,000. MetLife Investment Management LLC raised its stake in Solid Biosciences by 129.1% during the third quarter. MetLife Investment Management LLC now owns 13,699 shares of the company’s stock worth $95,000 after acquiring an additional 7,719 shares in the last quarter. Valence8 US LP bought a new position in shares of Solid Biosciences in the third quarter worth about $110,000. Finally, XTX Topco Ltd bought a new position in shares of Solid Biosciences in the third quarter worth about $121,000. 81.46% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on the stock. Chardan Capital reiterated a “buy” rating and set a $15.00 price objective on shares of Solid Biosciences in a research report on Monday, November 11th. HC Wainwright reaffirmed a “buy” rating and set a $16.00 target price on shares of Solid Biosciences in a research note on Friday, January 10th. Wedbush assumed coverage on Solid Biosciences in a research note on Friday, December 13th. They issued an “outperform” rating and a $16.00 price target for the company. JMP Securities initiated coverage on Solid Biosciences in a report on Tuesday, December 10th. They set an “outperform” rating and a $15.00 price objective on the stock. Finally, Truist Financial started coverage on Solid Biosciences in a report on Wednesday, January 8th. They issued a “buy” rating and a $16.00 target price for the company. Nine equities research analysts have rated the stock with a buy rating and four have given a strong buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Buy” and a consensus target price of $15.30.

Solid Biosciences Stock Performance

Shares of SLDB opened at $4.03 on Friday. The business has a 50-day moving average of $3.77 and a 200-day moving average of $5.84. Solid Biosciences Inc. has a 1 year low of $2.88 and a 1 year high of $15.05.

Insider Buying and Selling at Solid Biosciences

In related news, insider Jessie Hanrahan sold 4,610 shares of Solid Biosciences stock in a transaction on Tuesday, December 3rd. The shares were sold at an average price of $5.60, for a total transaction of $25,816.00. Following the completion of the transaction, the insider now owns 14,235 shares of the company’s stock, valued at $79,716. This trade represents a 24.46 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, COO David T. Howton sold 5,072 shares of the company’s stock in a transaction on Tuesday, December 3rd. The shares were sold at an average price of $5.60, for a total transaction of $28,403.20. Following the sale, the chief operating officer now directly owns 15,663 shares in the company, valued at $87,712.80. This trade represents a 24.46 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 26,069 shares of company stock valued at $137,301. 13.63% of the stock is currently owned by company insiders.

Solid Biosciences Profile

Solid Biosciences Inc, a life science company, develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; and SGT-501 to treat Catecholaminergic polymorphic ventricular tachycardia.